Matthew Stanton, CFA
Stock Analyst at Jefferies
(0.64)
# 4,029
Out of 4,534 analysts
21
Total ratings
42.9%
Success rate
-13.9%
Average return
Main Sectors:
Stocks Rated by Matthew Stanton, CFA
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYRX Cryoport | Maintained: Hold | $9.5 → $13 | $15.71 | -17.25% | 6 | Jun 8, 2026 | |
| RGEN Repligen | Maintained: Hold | $135 → $142 | $145.49 | -2.40% | 7 | May 5, 2026 | |
| AZTA Azenta | Maintained: Buy | $42 → $35 | $26.26 | +33.28% | 5 | Apr 1, 2026 | |
| MRVI Maravai LifeSciences Holdings | Maintained: Buy | $10 | $6.99 | n/a | 1 | Mar 18, 2025 | |
| LAB Standard BioTools | Initiated Coverage: Buy | $3.25 | $0.85 | n/a | 1 | Apr 4, 2024 | |
| BLFS BioLife Solutions | Initiated Coverage: Buy | $22 | $29.09 | n/a | 1 | Apr 4, 2024 |
Cryoport
Jun 8, 2026
Maintained: Hold
Price Target: $9.5 → $13
Current: $15.71
Upside: -17.25%
Repligen
May 5, 2026
Maintained: Hold
Price Target: $135 → $142
Current: $145.49
Upside: -2.40%
Azenta
Apr 1, 2026
Maintained: Buy
Price Target: $42 → $35
Current: $26.26
Upside: +33.28%
Maravai LifeSciences Holdings
Mar 18, 2025
Maintained: Buy
Price Target: $10
Current: $6.99
Upside: n/a
Standard BioTools
Apr 4, 2024
Initiated Coverage: Buy
Price Target: $3.25
Current: $0.85
Upside: n/a
BioLife Solutions
Apr 4, 2024
Initiated Coverage: Buy
Price Target: $22
Current: $29.09
Upside: n/a